<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038220</url>
  </required_header>
  <id_info>
    <org_study_id>M00-154</org_study_id>
    <nct_id>NCT00038220</nct_id>
    <nct_alias>NCT00006189</nct_alias>
  </id_info>
  <brief_title>Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the
      growth of HIV in patients infected with the virus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in each group demonstrating complete suppression of viral replication at Week 144.</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have HIV Infection.

          -  Age 18 to 65 years old.

          -  Show no signs of recent illness other than HIV infection.

          -  Agree to use a barrier method of birth control during the study and for 30 days after
             study.

        Exclusion Criteria:

          -  Are unable to follow study requirements (in the opinion of the investigator).

          -  Are pregnant or breast-feeding.

          -  Are unable to take medications by mouth.

          -  Have chronic nausea or vomiting.

          -  Have cancer other than Kaposi's sarcoma or basal cell carcinoma.

          -  Have active, serious infections (other than HIV) requiring antibiotic injections
             within 15 days prior to screening.

          -  Are taking any medications that are not allowed with ABT-378/r and efavirenz.

          -  Are taking or have taken any other experimental drugs, antiretroviral drugs, or drugs
             that affect the immune system within 30 days of start of study without consent of the
             medical monitor.

          -  Are receiving or have received radiation therapy within 30 days of start of study
             without consent of the medical monitor.

          -  Have a history of drug abuse or mental illness that would prevent the patient from
             following the protocol requirements.

          -  Have a history of kidney or bone disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Brun, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Head, Antiviral Global Project Team</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aaron Diamond AIDS Research Center - Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2002</study_first_submitted>
  <study_first_submitted_qc>May 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2002</study_first_posted>
  <last_update_submitted>July 26, 2006</last_update_submitted>
  <last_update_submitted_qc>July 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2006</last_update_posted>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

